BioInvent Interim Report 1 January – 30 June 2014

        Print
| Source: BioInvent International AB
Milestone payments and sale of product rights bring profit in second quarter
Second quarter 2014, April - June

  · Net sales for April – June 2014 amounted to SEK 32 (12) million.
  · Earnings after tax for April – June 2014: SEK 3.7 (-9.4) million.
  · Earnings after tax per share for April – June before and after dilution: SEK
0.04 (-0.13).
  · Cash flow from current operations and investment activities for April – June
2014: SEK -25 (-37) million.

Half year results 2014, January – June

  · Net sales for January – June 2014 amounted to SEK 34 (24) million.
  · Earnings after tax for January – June 2014: SEK -15 (-24) million.
  · Earnings after tax for January – June before and after dilution: SEK -0.17 (
-0.32).
  · Liquid funds as of 30 June 2014: SEK 74 (40) million. Cash flow from current
operations and investment activities for January – June 2014: SEK -48 (-60)
million.

Important events in the second quarter and after the reporting period

  · In the second quarter BioInvent received SEK 63.9 million through a rights
issue combined with a private placement. The rights issue was oversubscribed by
101% and amounted to SEK 48.9 million. The private placement of SEK 15 million
was subscribed by Henrik Rhenman through Rhenman Healthcare Equity L / S and
Peter Thelin through East Bay AB.
  · BioInvent sold back its rights to the drug candidate ADC-1013 to Alligator
Bioscience AB to focus resources on the fully owned drug development candidates.
  · BioInvent was granted a U.S. patent for BI-505 and apoptosis-inducing ICAM-1
antibodies. The patent provides broad protection for BI-505 which is in a phase
II study and which was developed using F.I.R.S.T.™, BioInvent's patented
discovery platform for antibody drug candidates and cellular target structures.
  · BioInvent has received milestone payments from Bayer and Servier totaling
EUR one million. The milestone payments are based on the development of
antibodies identified from BioInvent’s n-CoDeR® antibody library. The milestone
payments were triggered as Bayer enrolled the first patient in a phase I
clinical trial and Servier reached in vivo proof of concept against a specific
target structure.

Comments from the CEO
"In the second quarter, we demonstrated that we can generate significant revenue
from our technology. We have scaled up our marketing efforts and seen a growing
interest from international pharmaceutical and biotech companies for our
development platform F.I.R.S.T™ and for our key pipeline projects. Our research
programs are focused in immuno-oncology, the pharmaceutical market segment
expected to become the largest pharmaceutical market in oncology with a value
potential of over SEK 200 billion." says Michael Oredsson, CEO of BioInvent.

Contact
Any questions regarding this report will be answered by Michael Oredsson, CEO,
phone.+46 (0)46 286 85 67, mobile +46 (0)707 18 89 30. The report is also
available at www.bioinvent.com

Information disclosed in this half year report is provided herein pursuant to
the Swedish Securities Markets Act and/or the Swedish Financial Instruments
Trading Act. The information was submitted for publication at 8.40 a.m. CET, on
24 July, 2014.


BioInvent International AB is a research-based pharmaceutical company focused on
discovery and development of innovative antibody-based drugs against cancer.

The company has unique expertise in antibody drug development from initial
concept to late clinical phase. The screening tool F.I.R.S.T.TM and the antibody
library n-CoDeR® are two patented tools that enable identification of relevant
human antibodies and disease targets during the discovery phase. The scope and
strength of this platform is also used to develop antibody-based drugs in
collaboration with partners who finance the development of the new drug, and
provide BioInvent the right to milestone payments and royalties on sales. These
partners include Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Servier
and Xoma.